Document Detail


Percutaneous closure of ventricular septal defects. State of the art.
MedLine Citation:
PMID:  17255815     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Ventricular septal defect (VSD) is the most common congenital heart disease. Surgery has been performed for many years and is considered to be the gold standard for the treatment of VSD. However, it is associated with morbidity and mortality. Percutaneous closure of VSDs is performed under general anesthesia and with fluoroscopic and transesophageal echocardiographic guidance. Two devices of the Amplatzer family are currently used to close percutaneously muscular and perimembranous VSD with a closure rate of 97% (incidence of major complication 2.2%) and 97.5% (major acute complications in 1.2%), respectively. Occurrence of complete atrioventricular block is reported in 1% of subjects. Acquired VSD can occur as post-surgical residual leak, as a traumatic event or as consequence of a myocardial infarction. There are few data about percutaneous closure of post-surgical residual VSD and of traumatic VSD. As for the surgical approach, in patients with post-myocardial infarction VSD success rate of percutaneous closure is around 88% with a mortality of 22%. The currently available data show that, in experienced hands, percutaneous closure is a safe and effective procedure. Device closure of muscular and perimembranous VSD is a real alternative to the standard surgical approach with the advantage of a significantly reduced rate of mortality and complications.
Authors:
Gianfranco Butera; Massimo Chessa; Mario Carminati
Related Documents :
134185 - The rastelli operation for transposition of the great arteries. early and late results.
834465 - Atrio-ventricular conduction defects and arrhythmias by selective perfusion of the a-v ...
15224315 - Interatrial defect sizing by intracardiac and transesophageal echocardiography compared...
11605775 - Myocardial ischemia induced by anomalous aortic origin of the right coronary artery in ...
2408285 - The parasympathetic neuroeffector junction of the heart.
9889355 - Glucose transporter 3 (glut3) protein is present in human myocardium.
Publication Detail:
Type:  Case Reports; Journal Article; Review    
Journal Detail:
Title:  Journal of cardiovascular medicine (Hagerstown, Md.)     Volume:  8     ISSN:  1558-2027     ISO Abbreviation:  J Cardiovasc Med (Hagerstown)     Publication Date:  2007 Jan 
Date Detail:
Created Date:  2007-01-26     Completed Date:  2007-04-06     Revised Date:  2009-05-28    
Medline Journal Info:
Nlm Unique ID:  101259752     Medline TA:  J Cardiovasc Med (Hagerstown)     Country:  United States    
Other Details:
Languages:  eng     Pagination:  39-45     Citation Subset:  IM    
Affiliation:
Pediatric Cardiology, Istituto Policlinico San Donato, San Donato Milanese (MI), Italy. gianfra.but@lycos.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Adult
Cardiac Surgical Procedures* / adverse effects
Child
Child, Preschool
Cineangiography
Equipment Design
Female
Heart Catheterization* / adverse effects,  instrumentation,  methods
Heart Septal Defects, Ventricular / radiography,  surgery,  therapy*
Humans
Infant
Male
Middle Aged
Patient Selection
Radiography, Interventional
Treatment Outcome

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Patent foramen ovale and cryptogenic stroke. A critical review.
Next Document:  Septal defects: surgeons do it better.